P2, P1, P3, INF
Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
P1, P3, P6, P7, Z
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis
P1, P3, P4, Z, INF
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
P1, P3, P4, INF, Z
The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age
P1, P3, P4, INF
Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications
P7
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
P1, P3, P4, INF, Z
IGH Rearrangement Evolution in Adult KMT2Arearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring
P6
PREPRINT: Antibody-lectin chimeras for glyco-immune checkpoint blockade
bioRxiv – preprint
2022
P3, P6, P7, Z
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
P3, P4, P6, P7, Z
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
P1, P3, P4, INF, Z
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
P1, P4, P6
In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
P3
Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies
P1, P3, P6, Z
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia
P1, P6, P7, Z
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
P1, P3, P4, Z
PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia
P1, P3, P4, Z